아타라 바이오테라퓨틱스(ATRA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $9.77 (+0.62%), 시가총액 $0.08B, 52주 최저~최고 $4.18 ~ $18.09.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Resea
아타라 바이오테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
아타라 바이오테라퓨틱스의 현재 주가는 $9.77 (+0.62%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
아타라 바이오테라퓨틱스의 시가총액은 약 $0.08B입니다.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes T